Metabolism and Excretion of Liraglutide in Healthy Male Volunteers

NCT01517568 · Completed

Last updated 2026-05-28

This trial studied how the diabetes medication liraglutide is broken down and removed from the body in healthy adult men.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) treatment study

Participants 7 people Planned (estimated).

Who can join Ages 30–65 · male only

Timeline Started 2006-11 · est. completion 2006-12

Where 1 site · Netherlands

What this study is testing ClinicalTrials.gov NCT01517568 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of this trial is characterise the metabolic profile of liraglutide in plasma, urine, and faeces after a single injection of \[3H\]-liraglutide.

Treatments tested

liraglutide [3H] also known as [3H]-liraglutide Drug

A single dose of 0.75 mg will be given as a subcutaneous injection

Main thing measured	Profile and identity of the major metabolites of tritium labelled liraglutide in plasma, urine, and faeces
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Healthy
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01517568 ↗